An Open-Label, Randomized, Single-Dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Subjects
Latest Information Update: 19 Jan 2022
At a glance
- Drugs HCP1904-1 (Primary)
- Indications Essential hypertension
- Focus Pharmacokinetics
- Sponsors Hanmi Pharmaceutical
Most Recent Events
- 19 Jan 2022 New trial record